Clinical trials
Lung clinical trials
Below are recruiting lung clinical trials, each written for real people, not researchers. We’re tracking 2,898 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06643000Recruiting
High-dose furmonertinib combo for EGFR lung cancer with brain lining spread
This trial tests a strong dose of furmonertinib (a targeted pill) combined with two other drugs, bevacizumab and pemetrexed, for people with EGFR-mutated non-small cell lung cancer that has spread to the lining of the brain or spinal cord. It aims to see if this combination can better control the cancer and improve symptoms.
Zhengzhou, HenanAges 18 years+ - NCT06644066Recruiting
Oxygen-guided lung surgery for small tumors
This trial tests a new way to help surgeons find the right boundary between lung segments during surgery, using oxygen levels to guide them. It may help patients with small, early-stage lung tumors.
Xi'an, ShaanxiAges 18–75 - NCT06644430Recruiting
Burning lung spots plus systemic therapy for liver cancer
This trial tests whether burning away a few cancer spots in the lungs (called ablation) can help people with liver cancer who are already on a systemic treatment. If you have stable liver cancer and only a few lung spots that haven't grown, you may be eligible.
Beijing, Beijing MunicipalityAges 18–80 - NCT06645808RecruitingEarly Phase 1
PET imaging study for various solid tumors
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
Groningen, Provincie GroningenAges 18 years+ - NCT06652048RecruitingPhase 2
High-dose Furmonertinib for advanced lung cancer after progression
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06657898Recruiting
Complicated pneumonia in children in Southeast Europe
This study looks back at children who had a serious type of pneumonia (complicated pneumonia) between 2014 and 2024 in Southeast Europe. It aims to learn more about these infections to help improve care for kids in the future.
BelgradeAges 1 month–18 years - NCT06663306RecruitingPhase 1
Intrathecal pemetrexed and bevacizumab for lung cancer brain spread
This trial tests a treatment given directly into the fluid around the brain and spinal cord (intrathecal injection) using two drugs—pemetrexed and bevacizumab—for people with non-small cell lung cancer that has spread to that area (leptomeningeal metastases). It may be an option if your current treatment is no longer working.
ShanghaiAges 18 years+ - NCT06667167RecruitingPhase 2
First-line Keytruda + chemo then Keytruda + Trodelvy for SCLC
This trial tests a two-step treatment for extensive-stage small cell lung cancer: first, chemotherapy combined with Keytruda (an immunotherapy), followed by Keytruda plus Trodelvy (another targeted drug). The goal is to see if this combination helps people live longer and keeps the cancer under control.
Jerusalem, IsraelAges 18–99 - NCT06670833Recruiting
Tools to improve childhood pneumonia care
This trial tests new tools to help doctors diagnose and manage pneumonia in children. It may help children with cough or trouble breathing who are not severely ill.
DakarAges 2 months–12 years - NCT06671613Recruiting
Fasting-mimicking diet with immunotherapy for advanced lung cancer
This study combines a special periodic diet that mimics fasting with the standard immunotherapy drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer. The goal is to see if the diet can help the immunotherapy work better.
Long Beach, CaliforniaAges 18 years+ - NCT06673329RecruitingPhase 1
Brodalumab for immune-related side effects from cancer treatment
This trial tests if brodalumab, an antibody that blocks a specific immune pathway (IL-17), can help control side effects caused by immunotherapy cancer treatment. It is for people with advanced solid organ cancers who have immune-related side effects that are suspected to involve IL-17.
New York, New YorkAges 18 years+ - NCT06674343RecruitingPhase 3
Furmonertinib for advanced lung cancer with EGFR mutations
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06674811Recruiting
Childhood cancer surgery recovery study
This study looks at how children and young adults recover after surgery for solid tumors. It also includes their caregivers to understand how resilience affects recovery.
Rochester, MinnesotaAges 3–25 - NCT06676046Recruiting
Study of rare cholesterol and fat disorders
This study looks at people with rare or unusual cholesterol, fat, or heart-related conditions. It helps researchers learn more about these disorders and improve testing. You do not need to have a known diagnosis to join initially.
Bethesda, MarylandAges 10–90 - NCT06679777Recruiting
Swedish heart and lung imaging study 2
This study invites people who already took part in the first SCAPIS study to have follow-up heart and lung imaging. It helps researchers learn how these organs change over time.
GothenburgAges Any age - NCT06687941RecruitingPhase 1
Trial of AST-201 for GPC3-positive advanced solid tumors
This trial tests a new drug called AST-201 for people with advanced solid tumors that have a specific protein (GPC3). The study aims to see how safe and well-tolerated the drug is, and how the body processes it.
Goyang-si, Gyeonggi-doAges 19 years+ - NCT06691776Recruiting
Adaptive radiotherapy for five cancer types
This trial tests whether a newer type of daily CT scan (CBCT-guided adaptive radiotherapy) can safely and accurately deliver radiation to cancers of the prostate, cervix, bladder, lung, or head and neck. The goal is to better target the tumor and reduce side effects.
AmsterdamAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06696638Recruiting
Guiding breathing help with lung imaging vs. pressure in ARDS
This trial compares two ways to set the breathing machine for people with ARDS (a serious lung injury). One method uses a special imaging belt (EIT) to see how the lungs are working, while the other uses pressure measurements. The goal is to find the best way to adjust ventilator support to help you breathe more easily.
Wuhan, HubeiAges 18 years+ - NCT06702228Recruiting
Precision care for pulmonary fibrosis in Ireland
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
DublinAges 18–85 - NCT06702826RecruitingPhase 2
Cadonilimab plus radiation for lung cancer brain mets
This trial tests a combination of a targeted immunotherapy drug (cadonilimab) with a precise type of radiation to treat brain tumors that have grown after initial lung cancer treatment. The goal is to see if this approach can safely shrink brain metastases and improve outcomes.
Changsha, HunanAges 18–75 - NCT06707519Recruiting
Lung cancer breath and blood test study
This study is testing new breath and blood tests to detect lung cancer. It may help find better ways to diagnose and monitor non-small cell lung cancer.
Hamilton, OntarioAges 18 years+ - NCT07645222RecruitingPhase 1
Testing HS-20122 combined therapy for advanced lung cancer
This early-stage trial tests a new drug combination (HS-20122) for non-small cell lung cancer that has spread or cannot be surgically removed. You may qualify if your cancer has progressed despite prior treatment or you haven't received prior treatment yet.
Guangzhou, GuangdongAges 18–75 - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+
Hear when a new Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung?
- Yes. Clin2 currently lists 2,898 recruiting lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.